West Pharmaceutical Services, Inc.
WST
$263.51
-$15.59-5.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.90% | -1.12% | -1.92% | -1.71% | 0.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.90% | -1.12% | -1.92% | -1.71% | 0.38% |
| Cost of Revenue | 3.56% | 3.04% | 4.12% | 3.36% | 4.40% |
| Gross Profit | 1.70% | -8.15% | -11.64% | -9.96% | -6.14% |
| SG&A Expenses | -0.89% | -5.64% | -5.42% | 14.44% | 7.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 33.33% | -25.00% | -30.77% | 850.00% | -50.00% |
| Total Operating Expenses | 2.75% | 1.52% | 2.50% | 5.00% | 4.97% |
| Operating Income | 3.43% | -10.14% | -15.94% | -21.23% | -13.75% |
| Income Before Tax | -2.54% | -14.83% | -16.14% | -10.55% | 0.11% |
| Income Tax Expenses | 20.84% | 0.09% | -12.10% | -9.85% | -5.11% |
| Earnings from Continuing Operations | -7.09% | -17.85% | -16.97% | -10.69% | 1.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.09% | -17.85% | -16.97% | -10.69% | 1.20% |
| EBIT | 3.43% | -10.14% | -15.94% | -21.23% | -13.75% |
| EBITDA | 4.92% | -6.06% | -11.20% | -15.99% | -9.30% |
| EPS Basic | -5.50% | -16.35% | -15.47% | -9.46% | 2.02% |
| Normalized Basic EPS | 4.29% | -9.31% | -14.66% | -20.14% | -12.47% |
| EPS Diluted | -4.82% | -15.83% | -14.97% | -9.22% | 2.27% |
| Normalized Diluted EPS | 4.78% | -8.89% | -14.24% | -19.75% | -12.09% |
| Average Basic Shares Outstanding | -1.59% | -1.76% | -1.75% | -1.38% | -0.91% |
| Average Diluted Shares Outstanding | -2.04% | -2.20% | -2.22% | -1.85% | -1.36% |
| Dividend Per Share | 5.06% | 5.13% | 5.19% | 5.26% | 5.33% |
| Payout Ratio | 0.11% | 0.26% | 0.25% | 0.17% | 0.03% |